broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5 | ACH-000882 | IGR1_SKIN | HTS002 | 1 | 2.080156 | -0.710648 | 0.364658 | 1.316105 | 0.008638 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000882 |
BRD-K71847383-001-12-5 | ACH-000471 | LI7_LIVER | HTS002 | 1 | 1.585593 | -0.101126 | -0.001146 | 1.250215 | 0.004072 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000471 |
BRD-K71847383-001-12-5 | ACH-000670 | SBC5_LUNG | HTS002 | 1 | 1.978566 | -0.065714 | -0.144121 | 1.514264 | 0.374913 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000670 |
BRD-K71847383-001-12-5 | ACH-000048 | TOV112D_OVARY | HTS002 | 1 | 2.111336 | -0.285062 | 0.160421 | 1.29317 | 0.001283 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000048 |
BRD-K71847383-001-12-5 | ACH-000259 | KELLY_AUTONOMIC_GANGLIA | HTS002 | 1 | 2.044873 | -0.180587 | 0.161375 | 1.414224 | 0.006592 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000259 |
BRD-K71847383-001-12-5 | ACH-000599 | PATU8902_PANCREAS | HTS002 | 1 | 1.513314 | -0.395079 | 0.125334 | 1.145221 | 0.003954 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000599 |
BRD-K71847383-001-12-5 | ACH-000347 | QGP1_PANCREAS | HTS002 | 1 | 1.349151 | -0.221258 | 0.029495 | 1.128477 | 0.005413 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000347 |
BRD-K71847383-001-12-5 | ACH-000566 | SW1710_URINARY_TRACT | HTS002 | 1 | 2.127385 | -0.466755 | 0.162331 | 1.142718 | 0.000368 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000566 |
BRD-K71847383-001-12-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.013791 | 0.243031 | -0.127534 | 1.007658 | 0.028264 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001016 |
BRD-K71847383-001-12-5 | ACH-000395 | NCIH520_LUNG | HTS002 | 1 | 1.441373 | 0.066192 | -0.022403 | 1.246451 | 0.002191 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000395 |
BRD-K71847383-001-12-5 | ACH-000407 | SNU685_ENDOMETRIUM | HTS002 | 1 | 1.959478 | -0.062267 | -0.055122 | 1.400675 | 0.000359 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000407 |
BRD-K71847383-001-12-5 | ACH-000418 | SW1353_BONE | HTS002 | 1 | 1.729146 | -0.081587 | -0.038671 | 1.359396 | 0.054908 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000418 |
BRD-K71847383-001-12-5 | ACH-000191 | BHT101_THYROID | HTS002 | 1 | 1.838221 | -0.083379 | -0.071117 | 1.403202 | 0.03103 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000191 |
BRD-K71847383-001-12-5 | ACH-000941 | HEC1B_ENDOMETRIUM | HTS002 | 1 | 1.409375 | -0.255528 | -0.077893 | 1.153084 | 0.008129 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000941 |
BRD-K71847383-001-12-5 | ACH-000532 | SNU61_LARGE_INTESTINE | HTS002 | 1 | 2.496388 | -0.230521 | -0.044771 | 1.669876 | 0.028619 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000532 |
BRD-K71847383-001-12-5 | ACH-000677 | SW1573_LUNG | HTS002 | 1 | 1.106589 | -0.066012 | -0.031627 | 1.074442 | 28,966.235869 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000677 |
BRD-K71847383-001-12-5 | ACH-000619 | PECAPJ15_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 2.139722 | -0.200607 | 0.018532 | 1.44834 | 0.007645 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000619 |
BRD-K71847383-001-12-5 | ACH-000965 | RL952_ENDOMETRIUM | HTS002 | 1 | 2.215192 | -0.274107 | 0.187619 | 1.403407 | 0.004293 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000965 |
BRD-K71847383-001-12-5 | ACH-000210 | CADOES1_BONE | HTS002 | 1 | 1.176532 | -0.356517 | 0.021315 | 1.100047 | 0.198228 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000210 |
BRD-K71847383-001-12-5 | ACH-000803 | COLO668_LUNG | HTS002 | 1 | 2.818139 | 0.002983 | -0.115503 | 1.262934 | 489,903,777,809,829,100,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000803 |
BRD-K71847383-001-12-5 | ACH-000007 | LS513_LARGE_INTESTINE | HTS002 | 1 | 2.727918 | -0.32291 | 0.16352 | 1.550601 | 0.004783 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000007 |
BRD-K71847383-001-12-5 | ACH-000719 | RMGI_OVARY | HTS002 | 1 | 1.47171 | -1.178274 | 0.095912 | 1.327784 | 0.531399 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000719 |
BRD-K71847383-001-12-5 | ACH-000484 | VMRCRCW_KIDNEY | HTS002 | 1 | 1.545342 | 0.089947 | 0.003846 | 1.262234 | 0.185548 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000484 |
BRD-K71847383-001-12-5 | ACH-000688 | OV7_OVARY | HTS002 | 1 | 1.710586 | -0.005651 | -0.038411 | 1.492983 | 55,935,733,980,139,500,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000688 |
BRD-K71847383-001-12-5 | ACH-000351 | MKN1_STOMACH | HTS002 | 1 | 1.514879 | -0.322543 | 0.044991 | 1.187764 | 0.010062 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000351 |
BRD-K71847383-001-12-5 | ACH-000627 | LCLC103H_LUNG | HTS002 | 1 | 1.40064 | -0.010079 | -0.026267 | 1.204146 | 3.463374 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000627 |
BRD-K71847383-001-12-5 | ACH-000916 | NCIH1573_LUNG | HTS002 | 1 | 1.480394 | -0.059353 | -0.092716 | 1.312636 | 3,008.15651 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000916 |
BRD-K71847383-001-12-5 | ACH-000863 | DBTRG05MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.349858 | -0.144568 | -0.031159 | 1.230364 | 8.750605 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000863 |
BRD-K71847383-001-12-5 | ACH-000732 | PECAPJ41CLONED2_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.746025 | -0.098915 | -0.004813 | 1.317661 | 0.00359 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000732 |
BRD-K71847383-001-12-5 | ACH-000066 | HCC4006_LUNG | HTS002 | 1 | 1.241793 | 0.038858 | -0.033251 | 1.131332 | 0.000897 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000066 |
BRD-K71847383-001-12-5 | ACH-000015 | NCIH1581_LUNG | HTS002 | 1 | 0.851534 | 2.496968 | -0.089176 | 0.907082 | 0.023034 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000015 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.323627 | -0.312961 | 0.055511 | 1.264589 | 19.788211 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-000511_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000674 | NUGC4_STOMACH | HTS002 | 1 | 1.551132 | 0.03757 | -0.023317 | 1.279243 | 0.038322 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000674 |
BRD-K71847383-001-12-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | HTS002 | 1 | 1.786285 | -0.121503 | 0.017741 | 1.251865 | 0.000135 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000909 |
BRD-K71847383-001-12-5 | ACH-000237 | JHOM1_OVARY | HTS002 | 1 | 1.717977 | -0.040438 | -0.024462 | 1.353095 | 0.034595 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000237 |
BRD-K71847383-001-12-5 | ACH-000312 | SKNBE2_AUTONOMIC_GANGLIA | HTS002 | 1 | 1.692854 | 0.085024 | 0.011337 | 1.292156 | 3.38139 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000312 |
BRD-K71847383-001-12-5 | ACH-000390 | LUDLU1_LUNG | HTS002 | 1 | 1.459694 | -0.001629 | -0.149417 | 1.231453 | 414.639963 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000390 |
BRD-K71847383-001-12-5 | ACH-000901 | HCC1359_LUNG | HTS002 | 1 | 1.682342 | -0.740927 | 0.257602 | 1.32067 | 0.057405 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000901 |
BRD-K71847383-001-12-5 | ACH-000307 | PK1_PANCREAS | HTS002 | 1 | 1.797838 | -0.210562 | 0.105259 | 1.431259 | 0.18052 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000307 |
BRD-K71847383-001-12-5 | ACH-000289 | SNU466_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.381322 | 0.045057 | -0.005084 | 1.219618 | 0.000085 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000289 |
BRD-K71847383-001-12-5 | ACH-000309 | SKLU1_LUNG | HTS002 | 1 | 1.798838 | -0.023308 | 0.015615 | 1.386975 | 0.005372 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000309 |
BRD-K71847383-001-12-5 | ACH-000733 | NCIH1838_LUNG | HTS002 | 1 | 2.034714 | -0.170303 | 0.129263 | 1.485543 | 0.036401 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000733 |
BRD-K71847383-001-12-5 | ACH-000268 | SNU245_BILIARY_TRACT | HTS002 | 1 | 2.313456 | -0.000249 | 0.000106 | 1.656429 | 0.002003 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000268 |
BRD-K71847383-001-12-5 | ACH-000693 | KYSE180_OESOPHAGUS | HTS002 | 1 | 1.590214 | -0.308574 | 0.144666 | 1.277792 | 0.049852 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000693 |
BRD-K71847383-001-12-5 | ACH-000684 | KMRC1_KIDNEY | HTS002 | 1 | 1.328801 | -0.008006 | -0.017349 | 1.218517 | 978,415,259,504,676,000,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000684 |
BRD-K71847383-001-12-5 | ACH-000671 | HUH6_LIVER | HTS002 | 1 | 1.18801 | 0.413525 | -0.062578 | 1.131778 | 0.00543 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000671 |
BRD-K71847383-001-12-5 | ACH-000205 | PK59_PANCREAS | HTS002 | 1 | 1.585161 | -2.037387 | 0.116797 | 1.421691 | 0.66606 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000205 |
BRD-K71847383-001-12-5 | ACH-000720 | TCCSUP_URINARY_TRACT | HTS002 | 1 | 2.344244 | 0.086544 | -0.030695 | 1.560134 | 4.029657 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000720 |
BRD-K71847383-001-12-5 | ACH-000814 | HS939T_SKIN | HTS002 | 1 | 1.605862 | -0.385837 | 0.167186 | 1.282517 | 0.049997 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000814 |
BRD-K71847383-001-12-5 | ACH-000663 | OVTOKO_OVARY | HTS002 | 1 | 1.38006 | -0.094395 | 0.009593 | 1.153448 | 0.00117 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000663 |
BRD-K71847383-001-12-5 | ACH-000243 | DANG_PANCREAS | HTS002 | 1 | 1.883966 | 0.185311 | 0.005837 | 1.368636 | 0.536507 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000243 |
BRD-K71847383-001-12-5 | ACH-000255 | LMSU_STOMACH | HTS002 | 1 | 1.843483 | -0.102648 | 0.071293 | 1.431285 | 0.122526 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000255 |
BRD-K71847383-001-12-5 | ACH-000335 | MSTO211H_PLEURA | HTS002 | 1 | 1.821687 | -0.910079 | 0.167327 | 1.313535 | 0.023934 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000335 |
BRD-K71847383-001-12-5 | ACH-000147 | T47D_BREAST | HTS002 | 1 | 1.506421 | -0.109918 | -0.058095 | 1.205477 | 0.002238 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000147 |
BRD-K71847383-001-12-5 | ACH-000090 | PC3_PROSTATE | HTS002 | 1 | 1.380414 | -0.001639 | -0.018206 | 1.194714 | 285,048,019,687.513 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000090 |
BRD-K71847383-001-12-5 | ACH-000171 | VMRCRCZ_KIDNEY | HTS002 | 1 | 2.318304 | 0.191486 | 0.026362 | 1.658413 | 0.07911 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000171 |
BRD-K71847383-001-12-5 | ACH-000614 | RVH421_SKIN | HTS002 | 1 | 1.785291 | -0.298271 | 0.075745 | 1.352992 | 0.035325 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000614 |
BRD-K71847383-001-12-5 | ACH-000132 | JHOS2_OVARY | HTS002 | 1 | 1.414877 | -0.214227 | -0.106127 | 1.170485 | 0.012556 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000132 |
BRD-K71847383-001-12-5 | ACH-000274 | HS852T_SKIN | HTS002 | 1 | 1.655189 | -0.909414 | 0.226143 | 1.172918 | 0.007074 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000274 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.443519 | -0.066108 | 0.025176 | 1.212166 | 0.020853 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-000807_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000343 | NCIH522_LUNG | HTS002 | 1 | 1.725672 | -0.083615 | 0.018742 | 1.308402 | 0.002001 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000343 |
BRD-K71847383-001-12-5 | ACH-000022 | PATU8988S_PANCREAS | HTS002 | 1 | 1.718842 | -0.177556 | 0.008653 | 1.339862 | 0.040743 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000022 |
BRD-K71847383-001-12-5 | ACH-000192 | MFE280_ENDOMETRIUM | HTS002 | 1 | 2.346613 | -0.275436 | 0.273316 | 1.527348 | 0.012573 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000192 |
BRD-K71847383-001-12-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | HTS002 | 1 | 1.543219 | 0.036154 | -0.01509 | 1.255906 | 1.93617 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000959 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.574161 | 0.074685 | 0.016041 | 1.263311 | 0.738681 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-000028_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000637 | KYSE520_OESOPHAGUS | HTS002 | 1 | 1.533736 | -0.220301 | 0.054267 | 1.259167 | 0.058661 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000637 |
BRD-K71847383-001-12-5 | ACH-000968 | COLO792_SKIN | HTS002 | 1 | 2.511944 | -0.454143 | 0.124439 | 1.267316 | 0.000932 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000968 |
BRD-K71847383-001-12-5 | ACH-000155 | SW1990_PANCREAS | HTS002 | 1 | 1.342222 | -0.464096 | 0.254721 | 1.170806 | 0.077293 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000155 |
BRD-K71847383-001-12-5 | ACH-000775 | NCIH727_LUNG | HTS002 | 1 | 2.84504 | -0.388073 | -0.029273 | 1.436257 | 0.001802 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000775 |
BRD-K71847383-001-12-5 | ACH-000042 | PANC0203_PANCREAS | HTS002 | 1 | 1.577844 | -0.527769 | 0.194563 | 1.274882 | 0.059317 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000042 |
BRD-K71847383-001-12-5 | ACH-000994 | HEC59_ENDOMETRIUM | HTS002 | 1 | 1.507326 | -0.159198 | 0.015817 | 1.161046 | 0.000509 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000994 |
BRD-K71847383-001-12-5 | ACH-000277 | HCC1419_BREAST | HTS002 | 1 | 1.989964 | -0.18436 | 0.039165 | 1.463656 | 0.037549 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000277 |
BRD-K71847383-001-12-5 | ACH-000496 | NCIH1792_LUNG | HTS002 | 1 | 2.561179 | -0.144815 | 0.02005 | 1.375885 | 0.000021 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000496 |
BRD-K71847383-001-12-5 | ACH-000866 | NCIH1048_LUNG | HTS002 | 1 | 7.067238 | 1.425999 | 0.118365 | 1.048853 | 44.791706 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000866 |
BRD-K71847383-001-12-5 | ACH-000869 | NCIH1568_LUNG | HTS002 | 1 | 1.801582 | -0.219476 | 0.084953 | 1.435754 | 0.186604 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000869 |
BRD-K71847383-001-12-5 | ACH-000117 | EFM192A_BREAST | HTS002 | 1 | 1.90556 | -0.51927 | 0.05293 | 1.353405 | 0.022073 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000117 |
BRD-K71847383-001-12-5 | ACH-000678 | MKN7_STOMACH | HTS002 | 1 | 1.480753 | 0.131553 | -0.050706 | 1.171938 | 7.751818 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000678 |
BRD-K71847383-001-12-5 | ACH-000468 | PK45H_PANCREAS | HTS002 | 1 | 1.506566 | 1.099127 | 0.125005 | 1.252546 | 0.079246 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000468 |
BRD-K71847383-001-12-5 | ACH-000097 | ZR751_BREAST | HTS002 | 1 | 1.237778 | 0.042293 | -0.012681 | 1.140605 | 0.000012 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000097 |
BRD-K71847383-001-12-5 | ACH-000169 | RD_SOFT_TISSUE | HTS002 | 1 | 1.492686 | -0.203728 | -0.103216 | 1.202156 | 0.01144 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000169 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.371039 | 0.442354 | -0.010985 | 1.230005 | 0.017576 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-000010_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000895 | CL34_LARGE_INTESTINE | HTS002 | 1 | 2.697904 | -0.859279 | 0.378456 | 1.198158 | 0.001091 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000895 |
BRD-K71847383-001-12-5 | ACH-000414 | NCIH1944_LUNG | HTS002 | 1 | 1.565115 | -0.192419 | -0.013381 | 1.333469 | 0.593351 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000414 |
BRD-K71847383-001-12-5 | ACH-000649 | 786O_KIDNEY | HTS002 | 1 | 1.226091 | -0.033401 | 0.005444 | 1.111679 | 0.03783 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000649 |
BRD-K71847383-001-12-5 | ACH-000966 | IGROV1_OVARY | HTS002 | 1 | 1.5854 | -0.144324 | 0.004996 | 1.210406 | 0.001217 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000966 |
BRD-K71847383-001-12-5 | ACH-000950 | LOVO_LARGE_INTESTINE | HTS002 | 1 | 1.528719 | -0.365944 | 0.062414 | 1.159334 | 0.00458 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000950 |
BRD-K71847383-001-12-5 | ACH-000750 | LOXIMVI_SKIN | HTS002 | 1 | 2.441756 | -0.216679 | 0.036864 | 1.476095 | 0.002251 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000750 |
BRD-K71847383-001-12-5 | ACH-000270 | HPAC_PANCREAS | HTS002 | 1 | 2.112545 | 0.030894 | -0.058156 | 1.461119 | 5,739.122052 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000270 |
BRD-K71847383-001-12-5 | ACH-000535 | BXPC3_PANCREAS | HTS002 | 1 | 2.470032 | -0.114251 | 0.020717 | 1.654755 | 0.010918 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000535 |
BRD-K71847383-001-12-5 | ACH-000480 | HUH7_LIVER | HTS002 | 1 | 1.708395 | -0.024975 | -0.098421 | 1.516409 | 13,139,542,964,755,042 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000480 |
BRD-K71847383-001-12-5 | ACH-000897 | FTC238_THYROID | HTS002 | 1 | 2.096084 | 0.513997 | 0.19031 | 1.520283 | 0.104424 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000897 |
BRD-K71847383-001-12-5 | ACH-000389 | H4_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.562459 | -0.035113 | -0.002075 | 1.335112 | 5,046.565482 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000389 |
BRD-K71847383-001-12-5 | ACH-000862 | KMBC2_URINARY_TRACT | HTS002 | 1 | 1.529495 | -0.174552 | 0.200593 | 1.214612 | 0.007644 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000862 |
BRD-K71847383-001-12-5 | ACH-000776 | ONS76_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.369822 | -0.119445 | 0.050791 | 1.197524 | 0.253152 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000776 |
BRD-K71847383-001-12-5 | ACH-000023 | PATU8988T_PANCREAS | HTS002 | 1 | 1.322337 | 0.041285 | -0.034985 | 1.187078 | 0.000029 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000023 |
BRD-K71847383-001-12-5 | ACH-000011 | 253J_URINARY_TRACT | HTS002 | 1 | 2.154248 | -0.808272 | 0.303644 | 1.117569 | 0.000784 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000011 |
BRD-K71847383-001-12-5 | ACH-000973 | 639V_URINARY_TRACT | HTS002 | 1 | 1.824556 | -0.150881 | 0.075279 | 1.395944 | 0.045133 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000973 |
BRD-K71847383-001-12-5 | ACH-001024 | CHL1_SKIN | HTS002 | 1 | 1.909674 | -0.339502 | 0.147625 | 1.317523 | 0.00849 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001024 |
BRD-K71847383-001-12-5 | ACH-000971 | HCT116_LARGE_INTESTINE | HTS002 | 1 | 1.227644 | -0.395952 | 0.118114 | 1.137582 | 0.309118 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000971 |
BRD-K71847383-001-12-5 | ACH-000486 | KU1919_URINARY_TRACT | HTS002 | 1 | 1.358057 | -0.045279 | -0.02589 | 1.235093 | 135,882.073574 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000486 |